Form 4: Candel Therapeutics CFO Sells Shares to Cover Tax Obligations

Charles Schoch, Interim CFO of Candel Therapeutics, sold 9,511 shares of common stock on January 15, 2025, at a price of $7.225 per share to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On January 15, 2025, Charles Schoch, the Interim CFO of Candel Therapeutics, sold 9,511 shares of the company's common stock.
• The sale was executed at a price of $7.225 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting and settlement of restricted stock units.
• The sale was mandated by the Issuer's sell-to-cover policy and does not represent a discretionary sale by the Reporting Person.
• Following the transaction, Schoch directly owns 43,038 shares of Candel Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't reflect a change in the executive's outlook on the company.

Industry Context

Sales to cover tax obligations are a common practice when executives receive stock or options as part of their compensation. This is a standard procedure and doesn't necessarily indicate a lack of confidence in the company.

Stakeholder Impact

• The sale of shares by an executive could create short-term selling pressure on the stock.
• However, since the sale is due to tax obligations, the impact is likely to be minimal.

Key Dates